Compare DEI & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DEI | SNDX |
|---|---|---|
| Founded | 1971 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.8B |
| IPO Year | 2006 | 2016 |
| Metric | DEI | SNDX |
|---|---|---|
| Price | $10.47 | $20.58 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 13 |
| Target Price | $14.79 | ★ $80.23 |
| AVG Volume (30 Days) | ★ 2.6M | 1.2M |
| Earning Date | 02-10-2026 | 03-02-2026 |
| Dividend Yield | ★ 7.22% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $1,000,336,000.00 | $111,304,000.00 |
| Revenue This Year | $2.82 | $617.40 |
| Revenue Next Year | $1.47 | $115.70 |
| P/E Ratio | $84.47 | ★ N/A |
| Revenue Growth | 3.61 | ★ 595.65 |
| 52 Week Low | $10.46 | $8.58 |
| 52 Week High | $18.61 | $22.73 |
| Indicator | DEI | SNDX |
|---|---|---|
| Relative Strength Index (RSI) | 30.41 | 50.00 |
| Support Level | $10.71 | $19.79 |
| Resistance Level | $10.83 | $22.18 |
| Average True Range (ATR) | 0.25 | 1.05 |
| MACD | -0.03 | -0.08 |
| Stochastic Oscillator | 5.52 | 39.46 |
Douglas Emmett Inc is an integrated, self-administered, and self-managed REIT. It is an owner and operator of office and multifamily properties located in coastal submarkets in Los Angeles and Honolulu. The group focuses on owning, acquiring, developing, and managing a substantial market share of office properties and multifamily communities in neighborhoods with supply constraints, high-end executive housing, and key lifestyle amenities. Its properties are located in the Beverly Hills, Brentwood, Burbank, Century City, Olympic Corridor, Santa Monica, Sherman Oaks/Encino, Warner Center/Woodland Hills and Westwood submarkets of Los Angeles County, California, and in Honolulu, Hawaii. It has two business segments, the office segment and the multifamily segment.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.